Abstract 3449
Background
Early intracranial progression (ICP) reduce the efficacy of first line radiosurgery (SRS) for brain metastases. We aim to develop and validate a MR imaging-derived radiomic signature (RS) via deep learning approach for the prediction of 1-year disseminated ICP (DICP; more than or equal to 3 lesions and leptomeningeal carcinomatosis) in brain metastases patients treated with SRS.
Methods
A total of 1304 MRI-based radiomic features of pretreatment tumors were obtained from 208 patients with 451 lesions, who received first line SRS during August 2008 to January 2018. Variational autoencoder (VAE), trained with symmetric two encoded and decoded layers of neural network and 1,649,560 trainable parameters, was applied to reduce the dimensionality of radiomc features to 128 VAE-radiomic features. Penalized regression with 10-fold cross validation using least absolute shrinkage and selection operator performs features selection and construct RS to predict 1-year DICP events in train set of 150 patients, which was validated in test set of 58 patients. Harrell’s C-index was used to evaluate the discriminative ability of RS in both sets. The correlation of VAE-radiomic features and molecular features was analyzed by student t-test. Survival analysis was calculated using the Kaplan-Meier method.
Results
The RS yielded 1000 times bootstrapping corrected C-index of 0.746 and 0.747 for discrimination of 1-year DICP in the train and test cohorts, respectively. As for the subgroup of patients with lung (n = 175) and breast (n = 23) origin, the RS also showed good predictive performance with C-indices of 0.735 and 0.755, respectively. EGFR-mutation (n = 113) and ER (n = 22) status were associated with selected VAE-radiomic features No. 98 (p = 0.035) and No.127 (p = 0.44), respectively. Dichotomized risk category using RS of -0.769 (Youden index) as cut-off point yielded median overall survival of 57.7 months in low risk compared to 20.5 months in high risk group (p < 0.01).
Conclusions
The RS model provides a novel approach to predict 1-year DICP and survival in brain metastases receiving SRS, and is warranted to be integrated into GPA for optimal selection of patients treated with first line SRS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract